^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant

    i
    Associations
    News

    Trials

    Company:
    National Cancer Institute
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (NCT05642195)
    Phase 1/2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    12/30/2033
    Completion :
    12/30/2035
    PD-L1
    |
    PD-L1 expression
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant